Effects of EZH2 promoter polymorphisms and methylation status on oral squamous cell carcinoma susceptibility and pathology

American Journal of Cancer Research

Volumn 5, Issue 11, 2015, Pages 3475-3484

  Su, Kuo Jung ^a   Lin, Chiao Wen ^b,c   Chen, Mu Kuan ^b,d   Yang, Shun Fa ^b,c   Yu, Yung Luen ^a,e,f  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^c CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f ASIA UNIVERSITY   (Taiwan)

Author keywords

Bisulfite sequencing; EZH2; Methylation; Oral squamous cell carcinoma; Single nucleotide polymorphism (SNP)

Indexed keywords

TRANSCRIPTION FACTOR EZH2;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ACTIVITY; EZH2 GENE; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOUTH SQUAMOUS CELL CARCINOMA; ONCOGENE; PREDICTION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN POLYMORPHISM; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 85006197425     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Chung TT, Pan MS, Kuo CL, Wong RH, Lin CW, Chen MK and Yang SF. Impact of RECK gene polymorphisms and environmental factors on oral cancer susceptibility and clinicopathologic characteristics in Taiwan. Carcinogenesis 2011; 32: 1063-1068.
2. Nagaraj NS, Beckers S, Mensah JK, Waigel S, Vigneswaran N and Zacharias W. Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett 2006; 165: 182-194.
3. Sharan RN, Mehrotra R, Choudhury Y and Asotra K. Association of betel nut with carcinogenesis: revisit with a clinical perspective. PLoS One 2012; 7: e42759.
4. Feller L, Altini M and Lemmer J. Inflammation in the context of oral cancer. Oral Oncol 2013; 49: 887-892.
5. Liao CT, Wang HM, Ng SH, Yen TC, Lee LY, Hsueh C, Wei FC, Chen IH, Kang CJ, Huang SF and Chang JT. Good tumor control and survivals of squamous cell carcinoma of buccal mucosa treated with radical surgery with or without neck dissection in Taiwan. Oral Oncol 2006; 42: 800-809.
6. Wang B, Zhang S, Yue K and Wang XD. The recurrence and survival of oral squamous cell carcinoma: a report of 275 cases. Chin J Cancer 2013; 32: 614-618.
7. Zeng J, Kirk BD, Gou Y, Wang Q and Ma J. Genome-wide polycomb target gene prediction in Drosophila melanogaster. Nucleic Acids Res 2012; 40: 5848-5863.
8. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B and Cavalli G. Genome regulation by polycomb and trithorax proteins. Cell 2007; 128: 735-745.
9. Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH and Lee J. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013; 23: 839-852.
10. Chang CJ, Yang JY, Xia W, Chen CT, Xie X, Chao CH, Woodward WA, Hsu JM, Hortobagyi GN and Hung MC. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-beta-catenin signaling. Cancer Cell 2011; 19: 86-100.
11. Sasaki M, Ikeda H, Itatsu K, Yamaguchi J, Sawada S, Minato H, Ohta T and Nakanuma Y. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma. Lab Invest 2008; 88: 873-882.
12. Sauvageau M and Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 2010; 7: 299-313.
13. Blumenberg M, Gao S, Dickman K, Grollman AP, Bottinger EP and Zavadil J. Chromatin structure regulation in transforming growth factor-beta-directed epithelial-mesenchymal transition. Cells Tissues Organs 2007; 185: 162-174.
14. Shastry BS. SNP alleles in human disease and evolution. J Hum Genet 2002; 47: 561-566.
15. Kwok PY and Chen X. Detection of single nucleotide polymorphisms. Curr Issues Mol Biol 2003; 5: 43-60.
16. Wang DG, Fan JB, Siao CJ, Berno A, Young P, Sapolsky R, Ghandour G, Perkins N, Winchester E, Spencer J, Kruglyak L, Stein L, Hsie L, Topaloglou T, Hubbell E, Robinson E, Mittmann M, Morris MS, Shen N, Kilburn D, Rioux J, Nusbaum C, Rozen S, Hudson TJ, Lipshutz R, Chee M and Lander ES. Large-scale identification, mapping, and genotyping of single-nucle otide polymorphisms in the human genome. Science 1998; 280: 1077-1082.
17. Collins FS, Patrinos A, Jordan E, Chakravarti A, Gesteland R and Walters L. New goals for the U.S. Human Genome Project: 1998-2003. Science 1998; 282: 682-689.
18. Kulis M, Queiros AC, Beekman R and Martin-Subero JI. Intragenic DNA methylation in transcriptional regulation, normal differentiation and cancer. Biochim Biophys Acta 2013; 1829: 1161-1174.
19. Kulis M and Esteller M. DNA methylation and cancer. Adv Genet 2010; 70: 27-56.
20. Zhao L, Yu Y, Wu J, Bai J, Zhao Y, Li C, Sun W and Wang X. Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene 2014; 537: 197-202.
21. Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K and Ito H. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol 2009; 45: 39-46.
22. Lindstrom S, Schumacher FR, Cox D, Travis RC, Albanes D, Allen NE, Andriole G, Berndt SI, Boeing H, Bueno-de-Mesquita HB, Crawford ED, Diver WR, Gaziano JM, Giles GG, Giovannucci E, Gonzalez CA, Henderson B, Hunter DJ, Johansson M, Kolonel LN, Ma J, Le Marchand L, Pala V, Stampfer M, Stram DO, Thun MJ, Tjonneland A, Trichopoulos D, Virtamo J, Weinstein SJ, Willett WC, Yeager M, Hayes RB, Severi G, Haiman CA, Chanock SJ and Kraft P. Common genetic variants in prostate cancer risk prediction-results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). Cancer Epidemiol Biomarkers Prev 2012; 21: 437-444.
23. Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR, Thun MJ, Cox DG, Hankinson SE, Kraft P, Rosner B, Berg CD, Brinton LA, Lissowska J, Sherman ME, Chlebowski R, Kooperberg C, Jackson RD, Buckman DW, Hui P, Pfeiffer R, Jacobs KB, Thomas GD, Hoover RN, Gail MH, Chanock SJ and Hunter DJ. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010; 362: 986-993.
24. Crea F, Fornaro L, Paolicchi E, Masi G, Frumento P, Loupakis F, Salvatore L, Cremolini C, Schirripa M, Graziano F, Ronzoni M, Ricci V, Farrar WL, Falcone A and Danesi R. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients. Ann Oncol 2012; 23: 1207-1213.
25. Yoon KA, Gil HJ, Han J, Park J and Lee JS. Genetic polymorphisms in the polycomb group gene EZH2 and the risk of lung cancer. J Thorac Oncol 2010; 5: 10-16.
26. Subramaniam D, Thombre R, Dhar A and Anant S. DNA methyltransferases: a novel target for prevention and therapy. Front Oncol 2014; 4: 80.